262 related articles for article (PubMed ID: 34865628)
1. Cost-utility of as-needed ICS-formoterol versus to maintenance ICS in mild to moderate persistent asthma.
Buendía JA; Patiño DG
BMC Pulm Med; 2021 Dec; 21(1):397. PubMed ID: 34865628
[TBL] [Abstract][Full Text] [Related]
2. Cost-utility of as-needed combination low-dose budesonide-formoterol in adolescents mild asthma.
Buendía JA; Guerrero Patiño D; Talamoni HL
Pediatr Pulmonol; 2021 Dec; 56(12):3699-3705. PubMed ID: 34473917
[TBL] [Abstract][Full Text] [Related]
3. The cost-effectiveness of as-needed budesonide/formoterol versus low-dose inhaled corticosteroid maintenance therapy in patients with mild asthma in the UK.
FitzGerald JM; Arnetorp S; Smare C; Gibson D; Coulton K; Hounsell K; Golam S; Sadatsafavi M
Respir Med; 2020 Sep; 171():106079. PubMed ID: 32917353
[TBL] [Abstract][Full Text] [Related]
4. SMART therapy in adolescent and adults patients with moderate persistent asthma: a cost-utility analysis.
Buendía JA; Patiño DG
J Asthma; 2022 Dec; 59(12):2367-2374. PubMed ID: 34913809
[TBL] [Abstract][Full Text] [Related]
5. Symbicort® Maintenance and Reliever Therapy (SMART) and the evolution of asthma management within the GINA guidelines.
Lin J; Zhou X; Wang C; Liu C; Cai S; Huang M
Expert Rev Respir Med; 2018 Mar; 12(3):191-202. PubMed ID: 29400090
[TBL] [Abstract][Full Text] [Related]
6. The cost-effectiveness of as-needed budesonide-formoterol versus low-dose inhaled corticosteroid maintenance therapy in patients with mild asthma in Canada.
Sadatsafavi M; FitzGerald JM; O'Byrne PM; Soliman M; Sriskandarajah N; Vicente C; Golam SM
Allergy Asthma Clin Immunol; 2021 Oct; 17(1):108. PubMed ID: 34641954
[TBL] [Abstract][Full Text] [Related]
7. Budesonide-formoterol reliever therapy versus maintenance budesonide plus terbutaline reliever therapy in adults with mild to moderate asthma (PRACTICAL): a 52-week, open-label, multicentre, superiority, randomised controlled trial.
Hardy J; Baggott C; Fingleton J; Reddel HK; Hancox RJ; Harwood M; Corin A; Sparks J; Hall D; Sabbagh D; Mane S; Vohlidkova A; Martindale J; Williams M; Shirtcliffe P; Holliday M; Weatherall M; Beasley R;
Lancet; 2019 Sep; 394(10202):919-928. PubMed ID: 31451207
[TBL] [Abstract][Full Text] [Related]
8. An economic evaluation of budesonide/formoterol for maintenance and reliever treatment in asthma in general practice.
Goossens LM; Riemersma RA; Postma DS; van der Molen T; Rutten-van Mölken MP
Adv Ther; 2009 Sep; 26(9):872-85. PubMed ID: 19768640
[TBL] [Abstract][Full Text] [Related]
9. Budesonide/formoterol maintenance and reliever therapy in childhood asthma: Real-world effectiveness and economic assessment.
Yu Y; Cao W; Xiao Y; Li A; Huang H; Liu K; Hu L; Hou X; Xiang L; Wang X
Pediatr Pulmonol; 2023 Dec; 58(12):3406-3415. PubMed ID: 37818789
[TBL] [Abstract][Full Text] [Related]
10. Asthma control with ICS-formoterol reliever versus maintenance ICS and SABA reliever therapy: a post hoc analysis of two randomised controlled trials.
Hatter L; Houghton C; Bruce P; Holliday M; Eathorne A; Pavord I; Reddel HK; Hancox RJ; Braithwaite I; Oldfield K; Papi A; Weatherall M; Beasley R;
BMJ Open Respir Res; 2022 Aug; 9(1):. PubMed ID: 36007980
[TBL] [Abstract][Full Text] [Related]
11. Cost-utility of triple versus dual inhaler therapy in moderate to severe asthma.
Buendía JA; Patiño DG
BMC Pulm Med; 2021 Dec; 21(1):398. PubMed ID: 34865635
[TBL] [Abstract][Full Text] [Related]
12. Beginning to Address an Implementation Gap in Asthma: Clinicians' Views of Prescribing Reliever Budesonide-Formoterol Inhalers and SMART in the United States.
Krings JG; Sekhar TC; Chen V; Blake KV; Sumino K; James AS; Clover AK; Lenze EJ; Brownson RC; Castro M
J Allergy Clin Immunol Pract; 2023 Sep; 11(9):2767-2777. PubMed ID: 37245736
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of Budesonide-Formoterol for Maintenance and Reliever Therapy Among Patients With Poorly Controlled Asthma: A Systematic Review and Meta-analysis.
Beasley R; Harrison T; Peterson S; Gustafson P; Hamblin A; Bengtsson T; Fagerås M
JAMA Netw Open; 2022 Mar; 5(3):e220615. PubMed ID: 35230437
[TBL] [Abstract][Full Text] [Related]
14. Asthma maintenance and reliever therapy: Should this be the standard of care?
Cusack RP; Satia I; O'Byrne PM
Ann Allergy Asthma Immunol; 2020 Aug; 125(2):150-155. PubMed ID: 32339657
[TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness of budesonide/formoterol for maintenance and reliever asthma therapy in Denmark--cost-effectiveness analysis based on five randomised controlled trials.
Wickstrøm J; Dam N; Malmberg I; Hansen BB; Lange P
Clin Respir J; 2009 Jul; 3(3):169-80. PubMed ID: 20298400
[TBL] [Abstract][Full Text] [Related]
16. [Budesonide/formoterol maintenance and reliever therapy. A new treatment approach for adult patients with asthma].
Korn S; Vogelmeier C; Buhl R
Med Klin (Munich); 2008 May; 103(5):299-310. PubMed ID: 18484216
[TBL] [Abstract][Full Text] [Related]
17. Comparison of three alternatives for the management of moderate asthma in children aged 6-11 years: a cost-utility analysis.
Antonio Buendía J; Lindarte EF; Patiño DG
J Asthma; 2023 Apr; 60(4):761-768. PubMed ID: 35786145
[TBL] [Abstract][Full Text] [Related]
18. Budesonide/formoterol: a review of its use as maintenance and reliever inhalation therapy in asthma.
McCormack PL; Lyseng-Williamson KA
Drugs; 2007; 67(16):2407-31. PubMed ID: 17983258
[TBL] [Abstract][Full Text] [Related]
19. The Role of ICS-Containing Rescue Therapy Versus SABA Alone in Asthma Management Today.
Krings JG; Beasley R
J Allergy Clin Immunol Pract; 2024 Apr; 12(4):870-879. PubMed ID: 38237858
[TBL] [Abstract][Full Text] [Related]
20. Positioning As-needed Budesonide-Formoterol for Mild Asthma: Effect of Prestudy Treatment in Pooled Analysis of SYGMA 1 and 2.
Bateman ED; O'Byrne PM; FitzGerald JM; Barnes PJ; Zheng J; Lamarca R; Puu M; Parikh H; Alagappan V; Reddel HK
Ann Am Thorac Soc; 2021 Dec; 18(12):2007-2017. PubMed ID: 33979557
[No Abstract] [Full Text] [Related]
[Next] [New Search]
